Scott Gunther - Catalent President
| CTLT Stock | USD 60.75 0.25 0.41% |
President
Mr. Scott Gunther is Senior Vice President Quality Regulatory Affairs of the Company. Mr. Gunther was named our Senior Vice President of Quality Regulatory Affairs in May 2017. Mr. Gunther joined us in 2012 as Vice President, Quality and most recently oversaw the quality function for the United States sites in our Drug Delivery Solutions business unit. Previously, he concurrently served as an interim Vice President of Product Development for our Drug Delivery Solutions business unit. Prior to joining us, Mr. Gunther spent 22 years with BristolMyersSquibb in various roles of increasing responsibility. In his last role at Bristol, he held the position of Executive Director Quality Operations Americas, where he was responsible for quality operations at its manufacturing sites in the U.S., Puerto Rico, and Latin America since 2017.
| Age | 52 |
| Tenure | 7 years |
| Professional Marks | MBA |
| Address | 14 Schoolhouse Road, Somerset, NJ, United States, 08873 |
| Phone | 732 537 6200 |
| Web | https://www.catalent.com |
Latest Insider Transactions
Gunther holds a B.S. degree from the State University of New York College at Buffalo and an M.B.A. degree from Canisius College.Scott Gunther Latest Insider Activity
Tracking and analyzing the buying and selling activities of Scott Gunther against Catalent stock is an integral part of due diligence when investing in Catalent. Scott Gunther insider activity provides valuable insight into whether Catalent is net buyers or sellers over its current business cycle. Note, Catalent insiders must abide by specific rules, including filing SEC forms every time they buy or sell Catalent'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Scott Gunther over six months ago Disposition of 387 shares by Scott Gunther of Catalent at 56.2 subject to Rule 16b-3 |
Catalent Management Efficiency
Return On Tangible Assets is likely to gain to -0.15 in 2024. Return On Capital Employed is likely to gain to -0.08 in 2024. Total Current Liabilities is likely to drop to about 804.6 M in 2024. Liabilities And Stockholders Equity is likely to drop to about 6.6 B in 2024Catalent's management efficiency ratios could be used to measure how well Catalent manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Lisa Paley | Haleon plc | 57 | |
| Richard Daniell | Teva Pharma Industries | 57 | |
| Mark Neumann | Intracellular Th | 61 | |
| Mark Sabag | Teva Pharma Industries | 53 | |
| Katherine Strei | Emergent Biosolutions | 62 | |
| Andrew Plump | Takeda Pharmaceutical Co | 59 | |
| Juan Sanchez | Intracellular Th | 53 | |
| Atul Saran | Emergent Biosolutions | 51 | |
| Brendan OGrady | Teva Pharma Industries | 53 | |
| Hafrun Fridriksdottir | Teva Pharma Industries | 58 | |
| Kathleen Veit | Teva Pharma Industries | N/A | |
| Michael Olchaskey | Intracellular Th | N/A | |
| David Stark | Teva Pharma Industries | 55 | |
| Eliyahu Kalif | Teva Pharma Industries | 50 | |
| John Bardi | Intracellular Th | N/A | |
| Gianfranco Nazzi | Teva Pharma Industries | 50 | |
| Sven Dethlefs | Teva Pharma Industries | 55 | |
| Filippo Lanzi | Haleon plc | N/A | |
| Sean Kirk | Emergent Biosolutions | 45 | |
| Giles Platford | Takeda Pharmaceutical Co | 46 | |
| Christina Ackermann | Bausch Health Companies | 55 | |
Management Performance
| Return On Equity | -0.11 | ||||
| Return On Asset | -0.0018 |
Catalent Leadership Team
Elected by the shareholders, the Catalent's board of directors comprises two types of representatives: Catalent inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Catalent. The board's role is to monitor Catalent's management team and ensure that shareholders' interests are well served. Catalent's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Catalent's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Thomas Castellano, VP of Fin. and Investor Relations and Treasurer | ||
| Paul Surdez, Vice Relations | ||
| Joseph JD, General VP | ||
| Tom PEng, President Delivery | ||
| Trish Hunt, President Health | ||
| Peter Zippelius, Independent Director | ||
| David McErlane, Group Segment | ||
| Steven Fasman, Senior Vice President General Counsel and Corporate Secretary | ||
| Michael Hatzfeld, VP Officer | ||
| Kay Schmidt, Senior Vice President - Technical Operations | ||
| Karen Santiago, VP Office | ||
| Jonathan Arnold, President - Oral & Specialty Delivery | ||
| Ricky Hopson, Division President | ||
| John MBA, Executive Board | ||
| John Chiminski, Chairman of the Board, Chief Executive Officer | ||
| Donald Morel, Independent Director | ||
| John Greisch, Independent Director | ||
| Gregory Lucier, Independent Director | ||
| Rolf Classon, Independent Director | ||
| Michael Barber, Independent Director | ||
| Steven Esq, Corp VP | ||
| Karen Flynn, President - Biologics and Chief Commercial Officer | ||
| Michael Grippo, Senior Vice President - Strategy and Corporate Development | ||
| Matti Masanovich, Senior CFO | ||
| Julien Meissonnier, VP Officer | ||
| Christa Kreuzburg, Independent Director | ||
| Lisa Evoli, Senior Officer | ||
| Madhavan Balachandran, Independent Director | ||
| J Carroll, Independent Director | ||
| Scott Gunther, Senior Vice President - Quality & Regulatory Affairs | ||
| Wetteny Joseph, Chief Financial Officer, Senior Vice President | ||
| Alessandro Maselli, Senior Vice President - Global Operations | ||
| Dejan Lamesic, Head Development | ||
| Ricci Whitlow, President - Clinical Supply Services | ||
| Charles Lickfold, Senior Vice President, Chief Information Officer | ||
| Aristippos Gennadios, President - Softgel & Oral Technologies | ||
| Ricardo Pravda, Chief Human Resource Officer, Senior Vice President | ||
| Jack Stahl, Lead Independent Director | ||
| Z Mahdavi, Vice President of Open Innovation, Biologics, Cell and Gene Therapy | ||
| Rosemary Crane, Independent Director |
Catalent Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Catalent a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.11 | ||||
| Return On Asset | -0.0018 | ||||
| Profit Margin | (0.09) % | ||||
| Operating Margin | (0.07) % | ||||
| Current Valuation | 15.68 B | ||||
| Shares Outstanding | 181.51 M | ||||
| Shares Owned By Insiders | 0.50 % | ||||
| Shares Owned By Institutions | 87.76 % | ||||
| Number Of Shares Shorted | 9.06 M | ||||
| Price To Earning | 17.80 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Catalent Stock Analysis
When running Catalent's price analysis, check to measure Catalent's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalent is operating at the current time. Most of Catalent's value examination focuses on studying past and present price action to predict the probability of Catalent's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalent's price. Additionally, you may evaluate how the addition of Catalent to your portfolios can decrease your overall portfolio volatility.